niacin has been researched along with Hypertriglyceridemia in 85 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia." | 9.08 | A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 6.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Hypertriglyceridemia affects approximately 33% of the US population." | 6.52 | Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. ( Ito, MK, 2015) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 6.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| "We compared the effects of aerobic exercise and 6 wk of extended-release niacin on postprandial triglycerides in men with the metabolic syndrome." | 5.13 | Postprandial triglyceride responses to aerobic exercise and extended-release niacin. ( Grandjean, PW; Mahurin, AJ; Mestek, ML; Moncada-Jimenez, J; Plaisance, EP; Taylor, JK, 2008) |
| "Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia." | 5.08 | A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998) |
| " Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/niacin, pravastatin/magnesium, or pravastatin/placebo." | 5.08 | Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. ( Harris, WS; Nelson, J; O'Keefe, JH; Windsor, SL, 1995) |
| "MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids." | 4.84 | Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007) |
| "2%) of participants used 1 of 3 prescription medications indicated to treat hypertriglyceridemia (ie, fenofibrate, gemfibrozil, or niacin); this percentage was 2." | 3.75 | Hypertriglyceridemia and its pharmacologic treatment among US adults. ( Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G, 2009) |
| "Niacin has been reported to lower apoB and Lp(a) and to raise apoA-1." | 2.78 | Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). ( Albers, JJ; Kashyap, ML; Kwiterovich, PO; Marcovina, SM; O'Brien, KD; Robinson, JG; Slee, A; Xu, P, 2013) |
| " Further study is warranted to determine whether mealtime dosing would augment the clinical efficacy of extended-release niacin therapy." | 2.77 | Extended-release niacin acutely suppresses postprandial triglyceridemia. ( Dunbar, RL; Gadi, R; Goel, H; Hampson, J; Lilly, S; Mucksavage, ML; Nathanson, GA; Qamar, A; Rader, DJ; Usman, MH, 2012) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 2.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)." | 2.61 | New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019) |
| "Therefore, hypertriglyceridemia is recognized as a therapeutic target in the treatment of endothelial dysfunction." | 2.61 | Triglycerides and endothelial function: molecular biology to clinical perspective. ( Higashi, Y; Kajikawa, M, 2019) |
| "Hypertriglyceridemia is often a polygenic condition that can be affected by numerous interventions." | 2.58 | Hypertriglyceridemia: A review of the evidence. ( Elkins, C; Friedrich, D, 2018) |
| "Hypertriglyceridemia is increasingly identified in children and adolescents, owing to improved screening and higher prevalence of childhood obesity." | 2.55 | Approach to Hypertriglyceridemia in the Pediatric Population. ( Ashraf, AP; Sunil, B; Valaiyapathi, B, 2017) |
| "Hypertriglyceridemia affects approximately 33% of the US population." | 2.52 | Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. ( Ito, MK, 2015) |
| "Hypertriglyceridemia is an important marker of increased levels of highly atherogenic remnant-like particles." | 2.52 | Treatment of hypertriglyceridemia: a review of current options. ( Češka, R; Vrablík, M, 2015) |
| "Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk." | 2.50 | Recommendations for severe hypertriglyceridemia treatment, are there new strategies? ( Elisaf, MS; Filippatos, TD, 2014) |
| "Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases." | 2.46 | Lipid metabolism and hyperlipidemia in dogs. ( Steiner, JM; Xenoulis, PG, 2010) |
| "The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic." | 2.45 | Managing diabetic dyslipidemia: beyond statin therapy. ( Gadi, R; Neeli, H; Rader, DJ, 2009) |
| "Furthermore, severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis, irrespective of its effect on risk of cardiovascular disease." | 2.44 | Hypertriglyceridemia: its etiology, effects and treatment. ( Al-Shali, KZ; Hegele, RA; Yuan, G, 2007) |
| "Hypertriglyceridemia is associated with an increased risk of cardiovascular events and acute pancreatitis." | 2.44 | Management of hypertriglyceridemia. ( Lanier, JB; Oh, RC, 2007) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Hypertriglyceridemia is a commonly encountered problem in primary care practice." | 2.44 | Bridging the gap in treatment options for patients with hypertriglyceridemia. ( Hays, R; Underberg, JA, 2007) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 2.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "Hypertriglyceridemia has been recently recognized as a vascular risk factor, based on both clinical and experimental findings." | 2.38 | Pharmacological control of hypertriglyceridemia. ( Franceschini, G; Paoletti, R, 1993) |
| "Hypertriglyceridemia is a theoretical risk factor for CHD because of the increased production of atherogenic chylomicron and VLDL remnants, the inverse relationship present between serum triglyceride and HDL, the possible resultant increase in LDL attributable to remnant-reduced hepatic LDL-receptors as well as the formation of more dense and, therefore, more atherogenic LDL, and to the interaction between serum triglyceride and the fibrinolytic/coagulation system." | 2.38 | The triglyceride connection in atherosclerosis. ( Geurian, K; Pinson, JB; Weart, CW, 1992) |
| " Our aim was to find a rational NiAc dosing regimen that preserves FFA lowering, sufficient to reverse nonadipose tissue lipid accumulation and improve metabolic control, in obese Zucker rats." | 1.46 | Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S]. ( Baccega, T; Gabrielsson, J; Kroon, T; Oakes, ND; Olsén, A, 2017) |
| "The conventional methods of treatment of severe hypertriglyceridemia are dietary restriction and lipid lowering medications, mainly fibric acid derivatives." | 1.37 | Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. ( Pathak, RD; Pathak, SR; Poonuru, S; Vats, HS, 2011) |
| "Dyslipidemia is frequently found in association with obesity." | 1.37 | Obesity and dyslipidemia. ( Repas, T, 2011) |
| "Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities." | 1.35 | Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. ( Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (23.53) | 18.2507 |
| 2000's | 34 (40.00) | 29.6817 |
| 2010's | 30 (35.29) | 24.3611 |
| 2020's | 1 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Oh, RC | 2 |
| Trivette, ET | 1 |
| Westerfield, KL | 1 |
| Valaiyapathi, B | 1 |
| Sunil, B | 1 |
| Ashraf, AP | 1 |
| Elkins, C | 1 |
| Friedrich, D | 1 |
| Preston Mason, R | 1 |
| Kajikawa, M | 1 |
| Higashi, Y | 1 |
| Filippatos, TD | 1 |
| Elisaf, MS | 1 |
| Albers, JJ | 1 |
| Slee, A | 1 |
| O'Brien, KD | 1 |
| Robinson, JG | 1 |
| Kashyap, ML | 1 |
| Kwiterovich, PO | 1 |
| Xu, P | 1 |
| Marcovina, SM | 1 |
| Aye, MM | 1 |
| Kilpatrick, ES | 1 |
| Afolabi, P | 1 |
| Wootton, SA | 1 |
| Rigby, AS | 1 |
| Coady, AM | 1 |
| Sandeman, DD | 1 |
| Atkin, SL | 1 |
| Croyal, M | 1 |
| Ouguerram, K | 1 |
| Passard, M | 1 |
| Ferchaud-Roucher, V | 1 |
| Chétiveaux, M | 1 |
| Billon-Crossouard, S | 1 |
| de Gouville, AC | 1 |
| Lambert, G | 1 |
| Krempf, M | 1 |
| Nobécourt, E | 1 |
| Ito, MK | 1 |
| Vrablík, M | 1 |
| Češka, R | 1 |
| Grammer, T | 1 |
| Kleber, M | 1 |
| Silbernagel, G | 1 |
| Scharnagl, H | 1 |
| März, W | 1 |
| Handelsman, Y | 1 |
| Shapiro, MD | 1 |
| Kroon, T | 1 |
| Baccega, T | 1 |
| Olsén, A | 1 |
| Gabrielsson, J | 1 |
| Oakes, ND | 1 |
| Nichols, GA | 1 |
| Reynolds, K | 1 |
| Olufade, T | 1 |
| Kimes, TM | 1 |
| O'Keeffe-Rosetti, M | 1 |
| Sapp, DS | 1 |
| Anzalone, D | 1 |
| Fortmann, SP | 1 |
| Codario, RA | 1 |
| Plaisance, EP | 2 |
| Mestek, ML | 1 |
| Mahurin, AJ | 2 |
| Taylor, JK | 1 |
| Moncada-Jimenez, J | 1 |
| Grandjean, PW | 2 |
| Underberg, JA | 1 |
| Hays, R | 1 |
| Gandotra, P | 1 |
| Miller, M | 3 |
| Xenoulis, PG | 1 |
| Steiner, JM | 1 |
| Neeli, H | 1 |
| Gadi, R | 2 |
| Rader, DJ | 4 |
| Ford, ES | 1 |
| Li, C | 1 |
| Zhao, G | 1 |
| Pearson, WS | 1 |
| Mokdad, AH | 1 |
| Alagona, P | 1 |
| Toth, PP | 1 |
| Zarotsky, V | 1 |
| Sullivan, JM | 1 |
| Laitinen, D | 1 |
| Szafarz, M | 1 |
| Lomnicka, M | 1 |
| Sternak, M | 1 |
| Chlopicki, S | 1 |
| Szymura-Oleksiak, J | 1 |
| Jialal, I | 1 |
| Amess, W | 1 |
| Kaur, M | 1 |
| Souza, SA | 1 |
| Chow, DC | 1 |
| Walsh, EJ | 1 |
| Ford, S | 1 |
| Shikuma, C | 1 |
| Poonuru, S | 1 |
| Pathak, SR | 1 |
| Vats, HS | 1 |
| Pathak, RD | 1 |
| Wi, J | 1 |
| Kim, JY | 1 |
| Park, S | 1 |
| Kang, SM | 1 |
| Jang, Y | 1 |
| Chung, N | 1 |
| Shim, WH | 1 |
| Cho, SY | 1 |
| Lee, SH | 1 |
| Johansen, CT | 1 |
| Kathiresan, S | 1 |
| Hegele, RA | 2 |
| Klose, G | 1 |
| Custodis, F | 1 |
| Laufs, U | 1 |
| Repas, T | 1 |
| Sharpe, P | 1 |
| Hu, M | 1 |
| Chu, WC | 1 |
| Yamashita, S | 1 |
| Yeung, DK | 1 |
| Shi, L | 1 |
| Wang, D | 1 |
| Masuda, D | 1 |
| Yang, Y | 1 |
| Tomlinson, B | 1 |
| Usman, MH | 1 |
| Qamar, A | 1 |
| Lilly, S | 1 |
| Goel, H | 1 |
| Hampson, J | 1 |
| Mucksavage, ML | 1 |
| Nathanson, GA | 1 |
| Dunbar, RL | 2 |
| Berglund, L | 1 |
| Brunzell, J | 1 |
| Sacks, FM | 1 |
| Wooten, JS | 1 |
| Nambi, P | 1 |
| Gillard, BK | 1 |
| Pownall, HJ | 1 |
| Coraza, I | 1 |
| Scott, LW | 1 |
| Nambi, V | 1 |
| Ballantyne, CM | 1 |
| Balasubramanyam, A | 1 |
| Fung, MA | 1 |
| Frohlich, JJ | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 1 |
| Gouni-Berthold, I | 1 |
| Krone, W | 1 |
| Pins, JJ | 1 |
| Keenan, JM | 1 |
| Langenberg, P | 1 |
| Havas, S | 1 |
| Yuan, G | 1 |
| Al-Shali, KZ | 1 |
| Lanier, JB | 1 |
| Jacobson, TA | 1 |
| Schaefer, EJ | 1 |
| Brunzell, JD | 1 |
| Nagao, M | 1 |
| Oikawa, S | 1 |
| Yavasoglu, I | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Röggla, G | 1 |
| Fasan, M | 1 |
| Kapiotis, S | 1 |
| Holub, BJ | 1 |
| Oh, R | 1 |
| Raghavan, VA | 1 |
| Scanu, AM | 1 |
| Bamba, R | 1 |
| Knopp, RH | 1 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 1 |
| O'Keefe, JH | 2 |
| Harris, WS | 2 |
| Nelson, J | 1 |
| Windsor, SL | 1 |
| Bays, H | 1 |
| Lansing, AM | 1 |
| van der Wel, AM | 1 |
| Castro Cabezas, M | 1 |
| de Bruin, TW | 1 |
| Erkelens, DW | 1 |
| Franceschini, G | 2 |
| Paoletti, R | 2 |
| Lavie, CJ | 3 |
| Saloranta, C | 1 |
| Groop, L | 1 |
| Johansson, JO | 1 |
| Egberg, N | 1 |
| Asplund-Carlson, A | 1 |
| Carlson, LA | 2 |
| Grundy, SM | 2 |
| Vega, GL | 1 |
| McKenney, JM | 1 |
| McCormick, LS | 1 |
| Weiss, S | 1 |
| Koren, M | 1 |
| Kafonek, S | 1 |
| Black, DM | 1 |
| Gotto, AM | 1 |
| Scheen, AJ | 1 |
| Ginsberg, HN | 1 |
| Coughlan, BJ | 1 |
| Sorrentino, MJ | 1 |
| Milani, RV | 2 |
| Breuer, HW | 1 |
| Szapary, PO | 1 |
| Wierzbicki, AS | 1 |
| Reynolds, TM | 1 |
| Crook, MA | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Wahlberg, G | 1 |
| Walldius, G | 1 |
| Efendic, S | 1 |
| Geurian, K | 1 |
| Pinson, JB | 1 |
| Weart, CW | 1 |
| Mailander, L | 1 |
| Capurso, A | 1 |
| Tornvall, P | 1 |
| Hamsten, A | 1 |
| Johansson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289] | Phase 3 | 3,414 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.) | ||
| To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS)[NCT01118598] | Phase 4 | 34 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Influences of Physical Activity in the Profile of Trans Fatty Acids in the Serum of Individuals With Body Weight Changes[NCT03170973] | 66 participants (Anticipated) | Interventional | 2017-05-31 | Recruiting | |||
| Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur[NCT00969956] | 17 participants (Actual) | Observational | 2012-04-30 | Terminated (stopped due to Local regulations) | |||
| Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 45 |
| Placebo + Simvastatin | 38 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 282 |
| Placebo + Simvastatin | 274 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 171 |
| Placebo + Simvastatin | 158 |
(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months
| Intervention | participants (Number) |
|---|---|
| ERN + Simvastatin | 156 |
| Placebo + Simvastatin | 138 |
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 37.1 |
| Group 2 - Diet/Exercise Only | 38.7 |
| Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
| Group 4 - Diet/Exercise + Niacin | 41.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 162.2 |
| Group 2 - Diet/Exercise Only | 165.4 |
| Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
| Group 4 - Diet/Exercise + Niacin | 154 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 195.6 |
| Group 2 - Diet/Exercise Only | 200.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 184 |
| Group 4 - Diet/Exercise + Niacin | 190.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | ratio (Mean) |
|---|---|
| Group 1 - Usual Care | 5.2 |
| Group 2 - Diet/Exercise Only | 5.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
| Group 4 - Diet/Exercise + Niacin | 4.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 199 |
| Group 2 - Diet/Exercise Only | 216.9 |
| Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
| Group 4 - Diet/Exercise + Niacin | 177.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Body cell mass | Fat mass | |
| Group 1 - Usual Care | 59.6 | 36.8 |
| Group 2 - Diet/Exercise | 67.3 | 37.5 |
| Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
| Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | micrograms/ml (Mean) | |||
|---|---|---|---|---|
| Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
| Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
| Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
| Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
| Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
44 reviews available for niacin and Hypertriglyceridemia
| Article | Year |
|---|---|
Management of Hypertriglyceridemia: Common Questions and Answers.
Topics: Family Practice; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyper | 2020 |
Approach to Hypertriglyceridemia in the Pediatric Population.
Topics: Child; Fatty Acids, Omega-3; Fibric Acids; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Redu | 2017 |
Hypertriglyceridemia: A review of the evidence.
Topics: Diet; Exercise; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2018 |
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa | 2019 |
Triglycerides and endothelial function: molecular biology to clinical perspective.
Topics: Cardiovascular Diseases; Endothelial Cells; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethy | 2019 |
Recommendations for severe hypertriglyceridemia treatment, are there new strategies?
Topics: Algorithms; Blood Component Removal; Cardiovascular Diseases; Diet, Fat-Restricted; Fatty Acids, Ome | 2014 |
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Omega-3; Fibric Acids; Hum | 2015 |
Treatment of hypertriglyceridemia: a review of current options.
Topics: Animals; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyce | 2015 |
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; H | 2017 |
Bridging the gap in treatment options for patients with hypertriglyceridemia.
Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Comorbidity; Drug Monitoring; Drug | 2007 |
The role of triglycerides in cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Humans; Hypertriglyceridemia; | 2008 |
Lipid metabolism and hyperlipidemia in dogs.
Topics: Animals; Diet, Reducing; Dog Diseases; Dogs; Fatty Acids, Omega-3; Hyperlipidemias; Hypertriglycerid | 2010 |
Managing diabetic dyslipidemia: beyond statin therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angi | 2009 |
Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hydroxymethylgluta | 2009 |
Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.
Topics: Combined Modality Therapy; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reducta | 2009 |
Management of hypertriglyceridemia in the diabetic patient.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2010 |
Genetic determinants of plasma triglycerides.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angio | 2011 |
[Hypertricglyceridemia: prognostic impact and treatment options].
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet, R | 2011 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Demystifying triglycerides: a practical approach for the clinician.
Topics: Arteriosclerosis; Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2005 |
Hypertriglyceridemia-why, when and how should it be treated?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Comorbidity; Evidence-Based Medic | 2005 |
Dietary and nutraceutical options for managing the hypertriglyceridemic patient.
Topics: Dietary Carbohydrates; Energy Intake; Evidence-Based Medicine; Exercise; Fasting; Fish Oils; Humans; | 2006 |
Hypertriglyceridemia: its etiology, effects and treatment.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Management of hypertriglyceridemia.
Topics: Clofibric Acid; Diet; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrigly | 2007 |
Hypertriglyceridemia and cardiovascular risk reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu | 2007 |
Clinical practice. Hypertriglyceridemia.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Clofibric Acid; Combined Modality Therapy; Diet Therapy | 2007 |
[Intervention for hypertriglyceridemia].
Topics: Aged; Bezafibrate; Clofibric Acid; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; | 2007 |
Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypertriglyceri | 2008 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
[Triglycerides and atherosclerosis; treatment of hypertriglyceridemia].
Topics: Arteriosclerosis; Chylomicrons; Diet, Reducing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 1994 |
Pharmacological control of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Exercise; Fatty Acids, Omega-3; Humans; Hypertrigl | 1993 |
Drugs controlling triglyceride metabolism.
Topics: Anticholesteremic Agents; Arteriosclerosis; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Metf | 1993 |
Interactions between glucose and FFA metabolism in man.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Human | 1996 |
Nicotinic acid--the underused ally in the fight against coronary disease.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Utilization; Humans; Hypertriglyceridemia; Niacin; | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as | 1998 |
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-C | 1998 |
Triglyceride as a risk factor for coronary artery disease.
Topics: Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, | 1998 |
Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypertriglyceridemia; Hypolipi | 1999 |
Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role.
Topics: Coronary Disease; Diabetes Complications; Evidence-Based Medicine; Humans; Hypertriglyceridemia; Hyp | 2000 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyd | 2001 |
Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
Topics: Acids, Acyclic; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Epidemiologic Studies; | 2001 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
The triglyceride connection in atherosclerosis.
Topics: Alcohol Drinking; Arteriosclerosis; Coronary Disease; Diabetes Complications; Diet; Exercise; Humans | 1992 |
Drugs affecting triglycerides.
Topics: Benzhydryl Compounds; Clofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Niacin | 1991 |
10 trials available for niacin and Hypertriglyceridemia
| Article | Year |
|---|---|
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; | 2013 |
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Meth | 2014 |
Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients.
Topics: Apoprotein(a); Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Do | 2015 |
Postprandial triglyceride responses to aerobic exercise and extended-release niacin.
Topics: Adult; Analysis of Variance; Area Under Curve; Combined Modality Therapy; Cross-Over Studies; Dietar | 2008 |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Ac | 2010 |
Extended-release niacin acutely suppresses postprandial triglyceridemia.
Topics: Biomarkers; Black or African American; Cross-Over Studies; Delayed-Action Preparations; Double-Blind | 2012 |
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active; | 2013 |
Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia.
Topics: Adult; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combinatio | 1995 |
Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Blood Glucose; Drug Administration Schedule | 1997 |
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; H | 1998 |
31 other studies available for niacin and Hypertriglyceridemia
| Article | Year |
|---|---|
Drugs for hypertriglyceridemia.
Topics: Biomarkers; Cardiovascular Diseases; Drug Interactions; Fibric Acids; Fish Oils; Humans; Hydroxymeth | 2013 |
[Residual risk: The roles of triglycerides and high density lipoproteins].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Fibric Acids | 2016 |
Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].
Topics: Animals; Blood Glucose; Fasting; Fatty Acids; Glucose; Glucose Tolerance Test; Humans; Hypertriglyce | 2017 |
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, | 2017 |
Hypertriglyceridemia and cardiovascular disease management.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Disease Management; Fatty Acids, Omega-3; Female; Hu | 2007 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; M | 2009 |
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans; | 2009 |
Simultaneous determination of nicotinic acid and its four metabolites in rat plasma using high performance liquid chromatography with tandem mass spectrometric detection (LC/MS/MS).
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Hypertriglyceridemia; Niacin; Rats; Repr | 2010 |
Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia.
Topics: Adult; Delayed-Action Preparations; Glucose; HIV Seropositivity; Humans; Hypertriglyceridemia; Liver | 2010 |
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.
Topics: Adult; Gemfibrozil; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin | 2011 |
[Optimal lipid treatment: possibilities and current limitations].
Topics: Anion Exchange Resins; Anticholesteremic Agents; Blood Component Removal; Cardiovascular Diseases; C | 2011 |
Obesity and dyslipidemia.
Topics: Anti-Obesity Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dyslipidemias; Humans; H | 2011 |
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglycerid | 2011 |
Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Asian People; Body Weight; Diacylglycerol O-Acy | 2012 |
Patient information page from The Hormone Foundations. Patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides).
Topics: Fatty Acids, Omega-3; Fibric Acids; Humans; Hypertriglyceridemia; Life Style; Niacin; Triglycerides | 2012 |
Common problems in the management of hypertriglyceridemia.
Topics: Adult; Anticholesteremic Agents; Diagnosis, Differential; Diet; Dietary Fiber; Exercise; Fatty Acids | 2002 |
Niacin for high triglycerides.
Topics: Antiretroviral Therapy, Highly Active; Diet; Exercise; Humans; Hypertriglyceridemia; Niacin | 2002 |
Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects.
Topics: Alcohol Drinking; Body Mass Index; Cholesterol, HDL; Diet; Exercise; Female; Humans; Hypertriglyceri | 2007 |
Treating hypertriglyceridemia.
Topics: Adult; Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Heparin; Humans; Hydroxymethylglutar | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethyl | 2007 |
Hypertriglyceridemia.
Topics: Dietary Supplements; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Niaci | 2008 |
First-line therapies for lowering triglyceride levels.
Topics: Clofibric Acid; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceride | 2008 |
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hype | 1994 |
Sustained-release niacin for low levels of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Delayed-Action Preparations; Humans; Hypertriglyceridemia; Niacin | 1993 |
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol].
Topics: Cholesterol, HDL; Cholesterol, LDL; Exercise Therapy; Heart Diseases; Humans; Hypercholesterolemia; | 1998 |
Niacin in patients with diabetes mellitus and coronary artery disease.
Topics: Coronary Disease; Diabetes Complications; Humans; Hypertriglyceridemia; Niacin | 2001 |
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Dietary Fiber; Drug Therapy, Com | 2002 |
Effects of nicotinic acid on glucose tolerance and glucose incorporation into adipose tissue in hypertriglyceridaemia.
Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tol | 1992 |
Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease.
Topics: Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Humans; Hypertriglyceridemia; Male; | 1992 |
Normalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid.
Topics: Adult; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Female; Humans; Hypertriglyceridemia; Lipo | 1990 |